logo
Select company
Select metric
$ -22.61MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
19
Sector
47
Industry
64
History
23
$ 8.01Close
$ 1.9 - $ 14.3 52-Week Range
Ticker Information

Ticker

CRVO

Company Name

CERVOMED INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

CERVOMED INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

CRVO - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 0$ -22.61M$ -22.61M
3/31/2025$ 0$ -18.67M$ -18.67M
12/31/2024$ 0$ -16.29M$ -16.29M
9/30/2024$ 0$ -11.95M$ -11.95M
6/30/2024$ 0$ -5.04M$ -5.04M
3/31/2024$ 0$ -4.84M$ -4.84M
12/31/2023$ 0$ -2.17M$ -2.17M
9/30/2023$ 0$ -8.13M$ -8.13M
6/30/2023$ 0$ -13.08M$ -13.08M
3/31/2023$ 0$ -15.16M$ -15.16M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • CERVOMED INC's latest trailing twelve months (TTM) EBITDA stands at $ -14.71M.
  • Over the past 5 years, CERVOMED INC's average EBITDA has been $ -15.64M.
  • The median EBITDA for CERVOMED INC during this period was $ -15.67M
  • CERVOMED INC reached its highest EBITDA over the past 5 years at $ -2.17M.
  • The lowest EBITDA recorded by CERVOMED INC in the same timeframe $ -25.03M

CERVOMED INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
TCRX : TSCAN THERAPEUTICS INC $ -130.55MFATE : FATE THERAPEUTICS INC $ -155.49MCUE : CUE BIOPHARMA INC $ -36.06MSRZN : SURROZEN INC $ -31.83MOVID : OVID THERAPEUTICS INC $ -36.47MARMP : ARMATA PHARMACEUTICALS INC $ -10.66MCBUS : CIBUS INC $ -234.61MVERU : VERU INC $ -31.9MPSTV : PLUS THERAPEUTICS INC $ -14.57MORMP : ORAMED PHARMACEUTICALS INC $ -34.88M

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA
EBITDA for CERVOMED INC is calculated as follows: EBIT [ $ -14.82M ] + DepAmor [ $ 105.31K ]
(=) EBITDA [ $ -14.71M ]

CRVO - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -25.03M

Minimum

Sep 30, 2021

$ -2.17M

Maximum

Dec 31, 2023

$ -15.64M

Average

$ -15.67M

Median

EBITDA Benchmark Analysis

The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.9M with a standard deviation of $ 167.01M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.24K
min$ -493.3M
max$ 590.6M
average$ 58.9M
median$ 8.92M
std$ 167.01M